戻る Agenda
Closing Remarks and Session 13: How Drug Development Could Change Post-COVID
Session Chair(s)
Mark Kryah, PMP
Executive Director, Program Team Leader, Program and Portfolio Management
Ultragenyx Pharmaceutical Inc., United States
The COVID-19 pandemic forced everyone to think and work differently. The good news is that many changes, independent of COVID, should become new standards for the way drug development is planned and executed. This panel session will discuss some of the areas that may become future paradigms for drug development.
Learning Objective : - Describe how COVID-19 changed existing drug development practices
- Identify areas of change within your environment
- Apply these changes as new standards for drug development
Speaker(s)
Speaker
Mark Kryah, PMP
Ultragenyx Pharmaceutical Inc., United States
Executive Director, Program Team Leader, Program and Portfolio Management
Speaker
Athena S Papas, DMD, PHD
Tufts School of Dental Medicine, United States
Distinguished Professor Diagnostic Sciences
Speaker
Teresa Lamantia, MSN, RN
IQVIA, United States
Senior Vice President, Operational Transformation & Performance